An apparatus for regulating the concentration of glucose in the blood of a person includes: at least one glucose sensor that is arranged to measure the glucose concentration of the person, for example in the interstitial fluid or blood; a pump for selectively introducing at least one substance influencing the blood glucose levels into the body of the person, for instance by at least one cannula or catheter to be inserted into the body of said person, and a control for controlling said at least one substance influencing the blood glucose levels to be introduced to the person based on data received from said glucose sensor. Said apparatus includes at least one further sensor that is arranged to monitor a further characteristic of the person. The at least one further sensor may include an accelerometer, a heart rate sensor, a temperature sensor, a pH sensor, a ketone sensor, a GPS receiver, and/or a skin resistance sensor.

Described herein is a process suitable for extracorporeal lung support that relies on exposing blood, separated by a semipermeable membrane from the dialysis liquid. The dialysis liquid comprises a buffering agent and has a high buffering capacity for H+ ions. Carbon dioxide, bicarbonate and hydrogen cations can be efficiently transported across a semipermeable membrane to the dialysis liquid. This also allows for the regeneration and recycling of the dialysis liquid, and thus for its repeated use. The versatility of the dialysis liquid allows adjusting the pill of the dialysis liquid, add fluids to the dialysis liquid and/or to the blood in the extracorporeal circuit and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. Thus, the process is versatile, and suitable for treating or preventing respiratory acidosis, metabolic acidosis, diseases associated with lung malfunction and/or kidney malfunction and/or liver malfunction.

A method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy is provided. The method includes receiving cardiac data and determining a cardiac index based upon the cardiac data. The method includes determining an increased risk of death associated with epilepsy if the indices are extreme, issuing a warning of the increased risk of death and logging information related to the increased risk of death. Also presented is a second method for determining and responding in real-time to an increased risk of death relating to a patient with epilepsy comprising receiving at least one of arousal data, responsiveness data or awareness data and determining an arousal index, a responsiveness index or an awareness index, where the indices are based on arousal data, responsiveness data or awareness data respectively. The second method includes determining an increased risk of death related to epilepsy if indices are extreme values, issuing a warning of the increased risk of death and logging information related to the increased risk of death. A computer readable program storage device is also provided. Also provided is a method for receiving body data, determining a cardiac, an arousal, a responsiveness, or a kinetic index, determining an increased or increasing risk of death over a first time window relating to a patient with epilepsy and issuing a warning and logging relevant information.

Systems and methods are provided herein for treating a patient in cardiogenic shock. An intravascular heart pump system is inserted into vasculature of the patient. The heart pump system has a cannula, pump outlet, pump inlet, and rotor. The heart pump system is positioned within the patient such that the cannula extends across the patient's aortic valve, the pump inlet is located within the patient's left ventricle, and the pump outlet is located within the patient's aorta. Data related to time-varying parameters of the heart pump system is acquired from the heart pump system. A plurality of features are extracted from the data. A probability of survival of the patient is determined based on the plurality of features and using a prediction model. The heart pump system is operated to treat the patient.

A hub component for a vented connector including a generally elongate cylindrical body having a first end and a second end. The first end of the hub component includes one or more fingers or clips for engagement with one or more vents of the vented connector. The second end of the hub component can be configured for compatible engagement with a carbon dioxide detector.

A sensor component for use in a system for measuring concentration of analytes in fluid in a fluid line comprises one or more sensing elements having an optical property that varies with the concentration of the analytes, and engages with the fluid line such that the sensing elements are exposed to the fluid. The sensor component comprises a connector connecting to one or more optical waveguides, and transmits light between the waveguides and the sensing elements. The sensor component comprises one or more of a sampling port configured to provide fluidic access to the fluid line, a data storage medium storing data representing information about the sensor component, and a reflective element. Where it comprises a reflective element, the sensor component transmits light between the waveguides and the reflective element on a separate optical path from an optical path between the waveguides and the sensing elements.

Release of a neurological drug in a targeted region of a subject's brain by a drug delivery system (DDS) is intentionally caused by the subject watching or interacting with an audio/video-based task on an electronic display. The DDS is calibrated to release the neurological drug based on a particular pH, lactate level, blood flow, temperature, magnetic field, specific molecules released by brain cells, or other physiological factors within the target region. The interactive task produces the physiological factors in the brain in specific areas of pathology for which the drug is prescribed, and limits drug delivery at areas unaffected by illness where it could disrupt normal function, causing problematic side effects and preventing dose levels optimal for target impact. Feedback from the interactive task and associated cognitive probes also can adapt the interactive task or suggest new pharmacologic agents as the degree or primary focus of brain pathology changes during the course of treatment.

System and methods are provided for treating a patient that include a delivery device sized for introduction into a target site within a patient's body, a source of one or more therapeutic and/or diagnostic agents coupled to the delivery device, and a tubular member sized for introduction into the patient's vasculature to isolate the thoracic duct. Once the thoracic duct is isolated, fluid may be removed from the thoracic duct, e.g., to prevent the agents that transit from the target site into the thoracic duct from entering the patient's vasculature, and/or to modulate flow through the thoracic duct to modulate concentration and/or resident time of the agents at the target site. The one or more agents may include particles sized for preferential transit into the lymphatic system.

Described herein is a process suitable for extracorporeal lung support that relies on exposing blood, separated by a semipermeable membrane from the dialysis liquid. The dialysis liquid comprises a buffering agent and has a high buffering capacity for H+ ions. Carbon dioxide, bicarbonate and hydrogen cations can be efficiently transported across a semipermeable membrane to the dialysis liquid. This also allows for the regeneration and recycling of the dialysis liquid, and thus for its repeated use. The versatility of the dialysis liquid allows adjusting the pH of the dialysis liquid, add fluids to the dialysis liquid and/or to the blood in the extracorporeal circuit and to remove substances from the blood in the extracorporeal circuit, depending on the conditions and needs. Thus, the process is versatile, and suitable for treating or preventing respiratory acidosis, metabolic acidosis, diseases associated with lung malfunction and/or kidney malfunction and/or liver malfunction.

System and methods are provided for harvesting one or more organs, e.g., a lung from a donor body. In one embodiment, a distal end of a tubular member is introduced into the donor body's vasculature via a percutaneous access site, and the tubular member is manipulated until the distal end of the tubular member is disposed within the thoracic duct. Fluid is removed from the thoracic duct through the tubular member to a location exterior to the patient's body, and one or more organs are removed from the donor body. Optionally, one or more parameters within the thoracic duct or other parameters of the donor body may be monitored and fluid removal may be adjusted to reduce fluid accumulation within the one or more organs.